Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**Triglyceride biosynthesis pathway enzymes** are a group of enzymes that catalyze the stepwise formation of triglycerides (triacylglycerols), the body's main form of energy storage. The major, canonical pathway is the *glycerol-3-phosphate (Kennedy) pathway*, present in most tissues, and a secondary *monoacylglycerol pathway* predominates in the small intestine. Key enzymes in the canonical G3P pathway include: - **Glycerol-3-phosphate acyltransferase (GPAT)**: catalyzes the first, committed step converting glycerol-3-phosphate to lysophosphatidic acid. - **1-acylglycerol-3-phosphate acyltransferase (AGPAT)**: converts lysophosphatidic acid to phosphatidic acid. - **Phosphatidic acid phosphatase (PAP, mainly lipin proteins)**: hydrolyze phosphatidic acid to diacylglycerol. - **Diacylglycerol acyltransferase (DGAT, DGAT1 and DGAT2 isoforms)**: catalyze the final step attaching a fatty acyl-CoA to diacylglycerol to yield triglyceride[2][5][7]. Other enzymes involved can include acyl-CoA synthetase (activates fatty acids) and recently described alternative pathways involving proteins like DIESL and TMX1[6]. These enzymes are major regulators of energy homeostasis and lipid storage, and dysregulation is implicated in various diseases including obesity, type 2 diabetes, and fatty liver disease[1][7]. Multiple drugs target specific enzymes within this pathway (e.g., DGAT inhibitors) as potential metabolic disease therapeutics. **Note:** This "target" is a pathway and not a single molecular entity. Therefore, while individual enzymes in the pathway (e.g., diacylglycerol acyltransferase, or DGAT) are canonical drug targets and have specific abbreviations, the term "triglyceride biosynthesis pathway enzymes" collectively refers to a *group* of targets, not a specific molecule. This makes the entry *too broad* and *not strictly correct* as a single therapeutic target[2][5][7]. For structured data, each enzyme (GPAT, AGPAT, PAP/lipin, DGAT, etc.) should be its own canonical entry.
Inhibition of acyltransferases (e.g., DGAT inhibitors block the final step in triacylglycerol formation) - Modulation of lipogenesis through regulatory pathways
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Triglyceride biosynthesis pathway enzyme.